Skip to main content

. 1976 Feb;33(2):232–233. doi: 10.1038/bjc.1976.30

Letter: Digoxin does not prevent daunorubicin or adriamycin from binding to rat heart muscle.

B J Smith, D Kundv

PMCID: PMC2024933 PMID: 1259917

232

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Crowther D., Powles R. L., Bateman C. J., Beard M. E., Gauci C. L., Wrigley P. F., Malpas J. S., Fairley G. H., Scott R. B. Management of adult acute myelogenous leukaemia. Br Med J. 1973 Jan 20;1(5846):131–137. doi: 10.1136/bmj.1.5846.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
Lefrak E. A., Pitha J., Rosenheim S., Gottlieb J. A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 Aug;32(2):302–314. doi: 10.1002/1097-0142(197308)32:2<302::aid-cncr2820320205>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
Malpas J. S., Scott R. B. Daunorubicin in acute myelocytic leukaemia. Lancet. 1969 Mar 1;1(7592):469–470. doi: 10.1016/s0140-6736(69)91516-5. [DOI] [PubMed] [Google Scholar]
Middleman E., Luce J., Frei E., 3rd Clinical trials with adriamycin. Cancer. 1971 Oct;28(4):844–850. doi: 10.1002/1097-0142(1971)28:4<844::aid-cncr2820280407>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES